BOOK
Pancreatic Neoplasms, An Issue of Surgical Oncology Clinics of North America, E-Book
(2016)
Additional Information
Book Details
Abstract
This issue of Surgical Oncology Clinics of North America, guest edited by Nipun Merchant, MD, is devoted to Pancreatic Neoplasms. Dr. Merchant has assembled expert authors to review the following topics: Molecular and Genetic Basis of Pancreatic Carcinogenesis: Which Concepts May Be Clinically Relevant?; Role Of EUS and ERCP In The Clinical Assessment Of Pancreatic Neoplasms; Optimal Imaging Modalities For The Diagnosis and Staging Of Periampullary Lesions; Advances in the Surgical Management of Resectable and Borderline Resectable Pancreatic Cancer; Minimally Invasive Approaches to Pancreatic Surgery; Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer; Palliative Management of Unresectable Pancreatic Cancer; Spectrum and Classification of Cystic Lesions of the Pancreas; Therapeutic Approach to Cystic Neoplasms of the Pancreas; Clinical Presentation and Management of Pancreatic Neuroendocrine Tumors; State-of-the-Art Imaging of Pancreatic Neuroendocrine Tumors; Surgical Approaches to Pancreatic Neuroendocrine Tumors; and Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Pancreatic Neoplasms | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Foreword: Pancreatic Neoplasms\r | vii | ||
| Preface: Eat When You Can, Sleep When You Can, and Don’t Mess with the Pancreas\r | vii | ||
| Molecular and Genetic Basis of Pancreatic Carcinogenesis: Which Concepts May be Clinically Relevant?\r | vii | ||
| Optimal Imaging Modalities for the Diagnosis and Staging of Periampullary Masses\r | vii | ||
| Role of Endoscopic Ultrasonography and Endoscopic Retrograde\rCholangiopancreatography in the Clinical Assessment of Pancreatic Neoplasms\r | vii | ||
| Minimally Invasive Approaches to Pancreatic Surgery\r | viii | ||
| Advances in the Surgical Management of Resectable and Borderline Resectable Pancreas Cancer\r | viii | ||
| Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer\r | viii | ||
| Palliative Management of Unresectable Pancreas Cancer\r | viii | ||
| Spectrum and Classification of Cystic Neoplasms of the Pancreas\r | ix | ||
| Therapeutic Approach to Cystic Neoplasms of the Pancreas\r | ix | ||
| Clinical Presentation and Diagnosis of Pancreatic Neuroendocrine Tumors\r | ix | ||
| State-of-the-art Imaging of Pancreatic Neuroendocrine Tumors\r | ix | ||
| Surgical Management of Pancreatic Neuroendocrine Tumors\r | x | ||
| Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy\r | x | ||
| SURGICAL ONCOLOGY\rCLINICS OF NORTH AMERICA\r | xi | ||
| FORTHCOMING ISSUES | xi | ||
| July 2016 | xi | ||
| October 2016 | xi | ||
| January 2017 | xi | ||
| RECENT ISSUES | xi | ||
| January 2016 | xi | ||
| October 2015 | xi | ||
| July 2015 | xi | ||
| Foreword: Pancreatic Neoplasms\r | xiii | ||
| Preface:\rEat When You Can, Sleep When You Can, and Don’t Mess with the Pancreas | xv | ||
| Molecular and Genetic Basis of Pancreatic Carcinogenesis | 227 | ||
| Key points | 227 | ||
| MULTISTEP PROGRESSION OF PANCREATIC DUCTAL ADENOCARCINOMA | 228 | ||
| KRAS | 229 | ||
| TELOMERE SHORTENING | 229 | ||
| CDKN2A | 229 | ||
| TP53 | 230 | ||
| SMAD4 | 230 | ||
| CLINICAL RELEVANCE OF CORE PANCREATIC DUCTAL ADENOCARCINOMA MUTATIONS | 230 | ||
| GERMLINE VARIANTS | 230 | ||
| CORE SIGNALING PATHWAYS IN PANCREATIC CANCER | 231 | ||
| USING GENOMIC SEQUENCING TO GUIDE THERAPY | 234 | ||
| SUMMARY | 235 | ||
| ACKNOWLEDGMENTS | 235 | ||
| REFERENCES | 235 | ||
| Optimal Imaging Modalities for the Diagnosis and Staging of Periampullary Masses | 239 | ||
| Key points | 239 | ||
| INTRODUCTION | 239 | ||
| PERIAMPULLARY MASSES | 240 | ||
| CROSS-SECTIONAL IMAGING TECHNIQUES | 240 | ||
| Multidetector Computed Tomography | 240 | ||
| MRI | 242 | ||
| IMAGING FINDINGS | 244 | ||
| Tumor Detection | 244 | ||
| Assessment of Tumor Extension | 246 | ||
| Distant Metastasis | 247 | ||
| STRUCTURED REPORTING | 249 | ||
| SUMMARY | 251 | ||
| REFERENCES | 251 | ||
| Role of Endoscopic Ultrasonography and Endoscopic Retrograde Cholangiopancreatography in the Clinical Assessment of Pancrea ... | 255 | ||
| Key points | 255 | ||
| ENDOSCOPIC ULTRASONOGRAPHY IN PANCREATIC NEOPLASMS | 255 | ||
| Pancreatic Cancer | 256 | ||
| Staging endoscopic ultrasonography | 256 | ||
| Endoscopic ultrasonography fine-needle aspiration | 257 | ||
| Pancreatic Neuroendocrine Tumors | 258 | ||
| Pancreatic Cyst Lesions | 258 | ||
| The Concept of Core Biopsy | 259 | ||
| Therapeutic Applications of Endoscopic Ultrasonography in Pancreatic Neoplasms | 260 | ||
| Endoscopic ultrasonography–guided celiac plexus neurolysis | 260 | ||
| Endoscopic ultrasonography–guided implantation therapy | 260 | ||
| Endoscopic ultrasonography–guided pancreatic cyst ablation | 260 | ||
| Endoscopic ultrasonography–guided drainage of postoperative pancreatic fluid collections | 261 | ||
| ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY IN PANCREATIC NEOPLASMS | 261 | ||
| Rationale for Tissue Sampling | 262 | ||
| Endoscopic Techniques | 263 | ||
| Biliary Stenting | 265 | ||
| Types of Biliary Stents | 266 | ||
| Plastic stents | 266 | ||
| Self-expanding metal stents | 266 | ||
| Choice of Stent Placement | 267 | ||
| Inoperable cancer | 267 | ||
| Preoperative biliary decompression | 267 | ||
| Technical Outcomes | 268 | ||
| Endoscopic Treatment Alternatives | 268 | ||
| SUMMARY | 269 | ||
| REFERENCES | 269 | ||
| Minimally Invasive Approaches to Pancreatic Surgery | 273 | ||
| Key points | 273 | ||
| INTRODUCTION | 273 | ||
| LAPAROSCOPIC DISTAL PANCREATECTOMY | 274 | ||
| Indications for Minimally Invasive Distal Pancreatectomy | 274 | ||
| Technique of Laparoscopic Distal Pancreatectomy | 274 | ||
| Outcomes of Laparoscopic Distal Pancreatectomy | 275 | ||
| ROBOT-ASSISTED DISTAL PANCREATECTOMY | 275 | ||
| Technique of Robot-Assisted Distal Pancreatectomy | 275 | ||
| Outcomes of Robot-Assisted Distal Pancreatectomy | 276 | ||
| LAPAROSCOPIC PANCREATICODUODENECTOMY | 277 | ||
| Anatomic Considerations When Considering Approach/Indications for Minimally Invasive Approach | 277 | ||
| Technique of Laparoscopic Pancreaticoduodenectomy | 279 | ||
| Outcomes of Laparoscopic Pancreaticoduodenectomy | 279 | ||
| ROBOT-ASSISTED PANCREATICODUODENECTOMY | 281 | ||
| Technique | 281 | ||
| Outcomes of Robot-Assisted Pancreaticoduodenectomy | 281 | ||
| REFERENCES | 284 | ||
| Advances in the Surgical Management of Resectable and Borderline Resectable Pancreas Cancer | 287 | ||
| Key points | 287 | ||
| INTRODUCTION | 288 | ||
| DETERMINING RESECTABILITY | 288 | ||
| Resectable Disease | 289 | ||
| Locally Advanced Disease | 289 | ||
| Borderline Resectable Disease | 290 | ||
| DIAGNOSTIC WORKUP | 292 | ||
| Imaging Modalities | 292 | ||
| The Role for Diagnostic Laparoscopy | 292 | ||
| VASCULAR RESECTION DURING PANCREATICODUODENECTOMY | 293 | ||
| Venous Resections | 293 | ||
| Splenic Vein Ligation and Sinistral Hypertension | 294 | ||
| Arterial Resections | 294 | ||
| Postoperative Anticoagulation | 295 | ||
| ABERRANT VASCULAR ANATOMY AND CELIAC STENOSIS | 295 | ||
| Replaced Right and Common Hepatic Arteries | 296 | ||
| Celiac Artery Stenosis | 296 | ||
| LYMPHADENECTOMY IN PANCREATIC CANCER | 296 | ||
| Extended Lymphadenectomy | 297 | ||
| PYLORUS-SPARING VERSUS STANDARD PANCREATICODUODENECTOMY | 297 | ||
| THE ROLE FOR MINIMALLY INVASIVE SURGERY | 298 | ||
| COMPLICATIONS FOLLOWING PANCREATICODUODENECTOMY | 298 | ||
| Delayed Gastric Emptying | 299 | ||
| Pancreatic Fistula | 300 | ||
| Hemorrhage | 301 | ||
| PALLIATIVE OPTIONS | 301 | ||
| SUMMARY | 303 | ||
| REFERENCES | 303 | ||
| Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer | 311 | ||
| Key points | 311 | ||
| INTRODUCTION | 311 | ||
| HISTORIC ADJUVANT SYSTEMIC TRIALS | 312 | ||
| CURRENT AND FUTURE AREAS OF INVESTIGATION IN ADJUVANT THERAPY | 315 | ||
| NEOADJUVANT THERAPY: AN EMERGING PARADIGM IN PANCREAS ADENOCARCINOMA | 317 | ||
| NEOADJUVANT RADIATION THERAPY TRIALS | 317 | ||
| GEMCITABINE-BASED NEOADJUVANT SYSTEMIC THERAPY TRIALS | 319 | ||
| NEOADJUVANT THERAPY WITH FOLFIRINOX | 320 | ||
| CURRENT AND EMERGING AREAS OF NEOADJUVANT INVESTIGATION | 320 | ||
| IMMUNOTHERAPY TRIALS | 322 | ||
| SUMMARY | 322 | ||
| REFERENCES | 323 | ||
| Palliative Management of Unresectable Pancreas Cancer | 327 | ||
| Key points | 327 | ||
| BACKGROUND | 327 | ||
| CURRENT TREATMENT OF UNRESECTABLE PANCREATIC CANCER | 328 | ||
| PALLIATIVE RESECTION | 329 | ||
| BILIARY DECOMPRESSION | 330 | ||
| GASTRIC DECOMPRESSION | 332 | ||
| PAIN CONTROL | 333 | ||
| SUMMARY | 334 | ||
| REFERENCES | 334 | ||
| Spectrum and Classification of Cystic Neoplasms of the Pancreas | 339 | ||
| Key points | 339 | ||
| INTRODUCTION | 339 | ||
| MUCINOUS CYSTIC NEOPLASMS | 340 | ||
| Introduction | 340 | ||
| Clinical Presentation | 340 | ||
| Pathophysiology | 340 | ||
| Pathology/Classification | 340 | ||
| Diagnosis | 341 | ||
| Management | 341 | ||
| SEROUS CYSTIC NEOPLASM | 341 | ||
| Introduction | 341 | ||
| Clinical Presentation | 341 | ||
| Pathophysiology | 341 | ||
| Pathology/Classification | 341 | ||
| Diagnosis | 342 | ||
| Management | 342 | ||
| CYSTIC PANCREATIC ENDOCRINE NEOPLASMS | 342 | ||
| Introduction | 342 | ||
| Clinical Presentation | 342 | ||
| Pathophysiology | 343 | ||
| Pathology/Classification | 343 | ||
| Diagnosis | 343 | ||
| Management | 343 | ||
| SOLID PSEUDOPAPILLARY NEOPLASM | 343 | ||
| Introduction | 343 | ||
| Clinical Presentation | 343 | ||
| Pathophysiology | 344 | ||
| Pathology/Classification | 344 | ||
| Diagnosis | 344 | ||
| Management | 344 | ||
| INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM | 344 | ||
| Introduction | 344 | ||
| Clinical Presentation | 345 | ||
| Pathophysiology | 345 | ||
| Pathology/Classification | 345 | ||
| Diagnosis | 345 | ||
| Management | 346 | ||
| SUMMARY | 347 | ||
| REFERENCES | 347 | ||
| Therapeutic Approach to Cystic Neoplasms of the Pancreas | 351 | ||
| Key points | 351 | ||
| INTRODUCTION | 351 | ||
| SEROUS CYSTADENOMA | 353 | ||
| Outcome and Long-Term Recommendations | 353 | ||
| MUCINOUS CYSTIC NEOPLASMS (CYSTADENOMA AND CYSTADENOCARCINOMA) | 353 | ||
| Outcome and Long-Term Recommendations | 354 | ||
| INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS OF THE PANCREAS | 354 | ||
| Branch Duct Intraductal Papillary Mucinous Neoplasms | 355 | ||
| Main Duct Intraductal Papillary Mucinous Neoplasms | 356 | ||
| Outcome and Long-Term Follow-up | 357 | ||
| LESS COMMON CYSTIC NEOPLASMS OF THE PANCREAS | 358 | ||
| Solid Pseudopapillary Neoplasms | 358 | ||
| Cystic Endocrine Neoplasms | 358 | ||
| SUMMARY | 358 | ||
| REFERENCES | 359 | ||
| Clinical Presentation and Diagnosis of Pancreatic Neuroendocrine Tumors | 363 | ||
| Key points | 363 | ||
| EPIDEMIOLOGY | 363 | ||
| Classification | 363 | ||
| Pathology, Staging, and Grading | 365 | ||
| Incidence | 365 | ||
| Etiology and Inherited Pancreatic Neuroendocrine Tumors Syndromes | 365 | ||
| CLINICAL BEHAVIORS AND DIAGNOSIS OF SPECIFIC PANCREATIC NEUROENDOCRINE TUMORS | 366 | ||
| Nonfunctional Pancreatic Neuroendocrine Tumors | 366 | ||
| Insulinoma | 366 | ||
| Gastrinoma | 367 | ||
| Glucagonoma | 368 | ||
| VIPoma | 369 | ||
| Somatostatinoma | 369 | ||
| GRFoma | 370 | ||
| ACTHoma | 370 | ||
| PTHrp-oma | 370 | ||
| Pancreatic Neuroendocrine Tumors Causing Carcinoid Syndrome | 370 | ||
| TUMOR BEHAVIOR AND PROGNOSIS | 371 | ||
| SUMMARY | 371 | ||
| REFERENCES | 371 | ||
| State-of-the-art Imaging of Pancreatic Neuroendocrine Tumors | 375 | ||
| Key points | 375 | ||
| INTRODUCTION | 375 | ||
| IMAGING TECHNIQUES | 376 | ||
| Computed Tomography | 376 | ||
| MRI | 378 | ||
| Nuclear Medicine | 382 | ||
| Endoscopic Ultrasonography | 387 | ||
| IMAGING FINDINGS | 387 | ||
| Functional Pancreatic Neuroendocrine Tumors | 387 | ||
| Insulinomas | 389 | ||
| Gastrinomas | 390 | ||
| NONFUNCTIONING PANCREATIC NEUROENDOCRINE TUMORS | 391 | ||
| POORLY DIFFERENTIATED PANCREATIC ENDOCRINE TUMORS | 392 | ||
| STAGING | 392 | ||
| Primary Tumor | 393 | ||
| Disease Beyond the Pancreas: Nodal and Distant Metastatic | 393 | ||
| Nodal disease | 393 | ||
| Liver metastases | 395 | ||
| Other Distant Metastases | 395 | ||
| SUMMARY | 397 | ||
| REFERENCES | 397 | ||
| Surgical Management of Pancreatic Neuroendocrine Tumors | 401 | ||
| Key points | 401 | ||
| INTRODUCTION | 401 | ||
| GENERAL FEATURES OF PANCREATIC NEUROENDOCRINE TUMORS | 402 | ||
| SURGICAL MANAGEMENT OF LOCALIZED PANCREATIC NEUROENDOCRINE TUMORS | 407 | ||
| Insulinoma | 407 | ||
| Gastrinoma | 409 | ||
| Nonfunctional Pancreatic Neuroendocrine Tumors | 412 | ||
| Other Functional Pancreatic Neuroendocrine Tumors | 413 | ||
| MANAGEMENT OF NEUROENDOCRINE LIVER METASTASES | 413 | ||
| ROLE OF LIVER TRANSPLANTATION IN TREATMENT OF NEUROENDOCRINE LIVER METASTASES | 416 | ||
| SUMMARY | 417 | ||
| REFERENCES | 417 | ||
| Medical Management of Pancreatic Neuroendocrine Tumors | 423 | ||
| Key points | 423 | ||
| INTRODUCTION | 423 | ||
| CLASSIFICATION OF PANCREATIC NEUROENDOCRINE TUMORS | 424 | ||
| GENETIC BASIS OF NEUROENDOCRINE TUMORS | 426 | ||
| Inherited Neuroendocrine Tumor Syndromes | 426 | ||
| SYSTEMIC TREATMENT OF ADVANCED PANCREATIC NEUROENDOCRINE TUMORS | 426 | ||
| Somatostatin Analogues | 426 | ||
| Somatostatin analogues and control of symptoms from hormone secretion | 427 | ||
| Somatostatin analogues and disease control | 427 | ||
| TARGETED THERAPY | 428 | ||
| Mechanistic Target of Rapamycin Inhibitors | 428 | ||
| Vascular endothelial growth factor pathway inhibitors | 429 | ||
| Cytotoxic Chemotherapy | 430 | ||
| Streptozocin-containing regimens | 430 | ||
| Dacarbazine- and temozolomide-containing regimens | 430 | ||
| FUTURE DIRECTIONS | 431 | ||
| Peptide Receptor Radionuclide Therapy | 431 | ||
| Combination therapy | 432 | ||
| Combining mechanistic target of rapamycin inhibitor and vascular endothelial growth factor pathway inhibitor | 432 | ||
| Combining mechanistic target of rapamycin inhibitor and somatostatin analogue | 432 | ||
| Combining mechanistic target of rapamycin inhibitor and chemotherapy | 433 | ||
| SUMMARY | 433 | ||
| REFERENCES | 433 |